http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2583599-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3190be5d4946a766d6e44b377544cbbb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 |
| filingDate | 2015-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_545c70c3e51002f64e7d6bce0b41a638 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8686fcf6831924d1cc7e5aa997e4da48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a55d1f84887c97fd236fde4d4e470d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1aebe8149cc600c499dcba78410ca1b |
| publicationDate | 2016-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2583599-C1 |
| titleOfInvention | Method for drug delivery to posterior eyeball segment structures |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be used to deliver drugs to structures of posterior segment of eyeball. Producing through puncture of eyeball membranes 27G port at a distance of 4.0 mm from limbus toward equator of eyeball in upper-outer quadrant. Straight cannula 27G, implant comprising, carried out in vitreal cavity depth mid vitreous to lens implant is introduced in upper third of vitreous cavity, cannula 27G is removed directly, 27G port is removed, performing subconjunctival injection of 0.4 ml of 1.5 % dexamethasone. Implant is a biodegradable polymer, layers which are homogeneously distributed in drug substance, layers of implant are formed as congruent to each other ellipsoids of revolution consisting of polymers and/or copolymers of glycosaminoglycans, lactic acid and polyvinylpyrrolidone and layers, saturated drug substance, alternated with layers, not saturated drug substance; solubility of each layer of implant is provided by hydrolysis of crosslinks and directly proportional to their number; multilayer biodegradable implant diameter is from 0.03 to 0.3 mm. n EFFECT: invention improves functional results of treatment of various vitreoretinal diseases due to controlled drug release in therapeutic concentration in a given period of time. n 1 cl, 1 ex |
| priorityDate | 2015-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.